GW Pharmaceuticals PLC (NASDAQ:GWPH) Downgraded to Hold at Zacks Investment Research

GW Pharmaceuticals PLC (NASDAQ:GWPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, July 24th.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

A number of other brokerages have also recently commented on GWPH. Maxim Group assumed coverage on GW Pharmaceuticals PLC in a research note on Thursday, April 20th. They set a “buy” rating and a $135.00 price objective on the stock. Cantor Fitzgerald restated a “buy” rating and set a $208.00 price objective on shares of GW Pharmaceuticals PLC in a research note on Tuesday, May 9th. BidaskClub upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. ValuEngine upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, TheStreet cut GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research note on Wednesday, May 10th. Five equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $147.94.

GW Pharmaceuticals PLC (GWPH) traded down 0.48% during midday trading on Monday, reaching $101.75. The company’s stock had a trading volume of 218,738 shares. GW Pharmaceuticals PLC has a 1-year low of $79.62 and a 1-year high of $137.88. The company’s market capitalization is $2.58 billion. The company has a 50 day moving average of $107.51 and a 200-day moving average of $113.53.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.73) by $0.34. The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $2.10 million. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. During the same quarter in the prior year, the firm earned ($0.05) EPS. Equities research analysts anticipate that GW Pharmaceuticals PLC will post ($5.28) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/11/gw-pharmaceuticals-plc-nasdaqgwph-downgraded-to-hold-at-zacks-investment-research-updated-updated.html.

Hedge funds have recently made changes to their positions in the stock. Creative Planning boosted its stake in shares of GW Pharmaceuticals PLC by 1.4% in the second quarter. Creative Planning now owns 2,532 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 35 shares during the last quarter. Advisor Group Inc. boosted its stake in shares of GW Pharmaceuticals PLC by 10.7% in the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 145 shares during the last quarter. Ameriprise Financial Inc. boosted its stake in shares of GW Pharmaceuticals PLC by 8.5% in the second quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 162 shares during the last quarter. HighTower Advisors LLC boosted its stake in shares of GW Pharmaceuticals PLC by 10.3% in the first quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 191 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in shares of GW Pharmaceuticals PLC by 23.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,376 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 264 shares during the last quarter. Hedge funds and other institutional investors own 75.77% of the company’s stock.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

What are top analysts saying about GW Pharmaceuticals PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GW Pharmaceuticals PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit